Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy

References

• Brown, D. A., and D. Elliott. 2016. Attachment disorder in adults. New York, NY: W.W.Norton.
   Google Scholar
• Carhart-Harris, R., L. Roseman, E. Haijen, D. Erritzoe, R. Watts, I. Branchi, and M. Kaelen. 2018, July. Psychedelics and the essential importance of context. Journal of Psychopharmacology 32 (7):725–31. Epub 2018 Feb 15. doi:10.1177/0269881118754710.
   PubMed Web of Science ®Google Scholar
• Chilukuri, H., R. Pothula, R. Pathapati, A. Manu, S. Jollu, and A. Shaik. 2014. Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian Journal of Psychological Medicine (36/1):71–76. doi:10.4103/0253-7176.127258.
   PubMedGoogle Scholar
• Collins, K., J. Murrough, A. Perez, D. Reich, D. Charney, and S. Mathew. 2010. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry 67 (2):139–45. doi:10.1016/j.biopsych.2009.08.038.
   PubMed Web of Science ®Google Scholar
• Cusin, C., G. Hilton, A. Nierenberg, and M. Fava. 2012. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. American Journal of Psychiatry 169:868–69. doi:10.1176/appi.ajp.2012.12020219.
   PubMed Web of Science ®Google Scholar
• Early, T. 2016. Making ketamine work in the long run. In The ketamine papers: Science,therapy and transformation, ed. P. Wolfson and G. Hartellius, 305–22. Santa Cruz, CA: MAPS Press.
   Google Scholar
• Feduccia, A., J. C. Holland, and M. C. Mithoefer. 2018. Progress and promise for the MDMA drug development program. Psychopharmacology 235 (2):561–71. doi:10.1007/s00213-017-4779-2.
   PubMed Web of Science ®Google Scholar
• Fontana, A. 1974. Terapia atidepresiva con ketamine. Acta psiquiatrica y psicologica de America latina 20:32.
   PubMed Web of Science ®Google Scholar
• Griffiths, R., M. Johnson, W. Richards, B. Richards, U. McCann, and R. Jesse. 2011. Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology (Berl) 218 (4):649–65. doi:10.1007/s00213-011-2358-5.
   PubMed Web of Science ®Google Scholar
• Hyde, S. J. 2015. Ketamine and depression. Tasmania: Xlibris.
   Google Scholar
• Jaitly, V. 2013. Sublingual ketamine in chronic pain: Service evaluation by examining more than 200 patient years of data. Journal of Observational Pain Medicine 1/2 (2013).
   Google Scholar
• Jansen, K. 2004. Ketamine: Dreams and realities. Santa Cruz, CA: MAPS.
   Google Scholar
• Khorramzadeh, E., and A. Lofty. 1973. The use of ketamine in psychiatry. Psychosomatics 14:344–46. doi:10.1016/S0033-3182(73)71306-2.
   PubMed Web of Science ®Google Scholar
• Kolp, E., M. S. Young, H. Friedman, E. Krupitsky, K. Jansen, and L. O’Connor. 2007. Ketamine-enhanced psychotherapy: Preliminary clinical observations on its effects in treating death anxiety. International Journal of Transpersonal Studies 26:1–17. doi:10.24972/ijts.
   Google Scholar
• Krupitsky, E., and A. Grinenko. 1997. Ketamine psychedelic therapy (KPT)—A review of the results of ten years of research. Journal of Psychoactive Drugs 29 (2):165–83. doi:10.1080/02791072.1997.10400185.
   PubMed Web of Science ®Google Scholar
• Krystal, J. H. 2007. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Medical Weekly 137 (15–16):215–16.
   PubMed Web of Science ®Google Scholar
• Krystal, J. H., L. P. Karper, J. P. Seibyl, G. K. Freeman, R. Delaney, J. D. Bremner, and D. S. Charney. 1994. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 51 (3):199–214. doi:10.1001/archpsyc.1994.03950030035004.
   PubMed Web of Science ®Google Scholar
• Krystal, J. H., S. Madonick, E. Perry, R. Gueorguieva, L. Brush, Y. Wray, A. Belger, and D. C. D’Souza. 2006. Potentiation of low dose ketamine effects by naltrexone: Potential implications for the pharmacotherapy of alcoholism. Neuropsychopharmacology 31 (8):1793–800. doi:10.1038/sj.npp.1300994.
   PubMed Web of Science ®Google Scholar
• Lara, D., L. Bisol, and L. Munari. 2013. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. The International Journal of Neuropsychopharmacology 16 (9):2111–17. doi:10.1017/S1461145713000485.
   PubMed Web of Science ®Google Scholar
• Luckenbaugh, D. A., M. J. Niciu, D. F. Ionescu, N. M. Nolan, E. M. Richards, N. E. Brutsche, and C. Zarate. 2014. Do the dissociative side effects of ketamine mediate antidepressant effects. Journal of Affective Disorders 159:56–61. doi:10.1016/j.jad.2014.02.017.
   PubMed Web of Science ®Google Scholar
• Matthew, S., and C. Zarate, editors. 2016. Ketamine for Treatment Resistant Depression. Switzerl: Adis, Springer International.
   Google Scholar
• McGirr, A., M. Berlim, D. Bond, M. Fleck, L. Yatham, and R. W. Lam. 2014. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine. doi:10.1017/S0033291714001603.
   PubMed Web of Science ®Google Scholar
• Millière, R., R. Carhart-Harris, L. Roseman, F. Trautwein, and A. Berkovich-Ohana. 2018, September 4. Psychedelics, meditation, and self-consciousness. Frontiers in Psychology 9:1475. doi: 10.3389/fpsyg.2018.01475.
   PubMed Web of Science ®Google Scholar
• Mithoefer, M. C., C. S. Grob, and T. D. Brewerton. 2016. Novel psychopharmacological therapies for psychiatric disorders: Psilocybin and MDMA. The Lancet Psychiatry 3 (5):481–88. Epub 2016 Apr 5. doi:10.1016/S2215-0366(15)00576-3.
   PubMed Web of Science ®Google Scholar
• Nour, M. M., L. Evans, D. Nutt, and R. L. Carhart-Harris. 2016, June 14. Ego-dissolution and psychedelics: Validation of the Ego-Dissolution Inventory (EDI). Frontiers in Human Neuroscience 10:269. doi: 10.3389/fnhum.2016.00269.eCollection2016.
   PubMed Web of Science ®Google Scholar
• R. M.A. Cappiello, A. Anand, D. Oren, G. Heninger, D. Charney, and J. Krystal. 2000. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 47 (4):351–54. doi:10.1016/S0006-3223(99)00230-9.
   PubMed Web of Science ®Google Scholar
• Rot, M., K. Collins, J. Murrough, A. Perez, D. Reich, D. Charney, and S. Mathew. 2015. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry 67/2:139–45. doi:10.1016/j.biopsych.2009.08.038.
   Web of Science ®Google Scholar
• Ryan, W., C. Marta, and R. Koek. 2016. Ketamine and depression: A review. In The ketamine papers, ed. P. Wolfson and G. Hartellius, 199–273. Santa Cruz, CA: MAPS.
   Google Scholar
• Schwartz, R. 1995. Internal family systems therapy. New York, NY: The Guilford Press.
   Google Scholar
• Sullivan, P. 2018. Using ketamine to treat addictions. Paper presented at the Kriya Conference, The Nueva School. Hillsborough, CA, November 4.
   Google Scholar
• Van Der Kolk, B. 2014. The body keeps the score. London, UK: The Penguin Group.
   Google Scholar
• Wallach, J. 2018. Pharmacokinetics and pharmacodynamics of ketamine (and Related Compounds). Paper Presented at the Kriya Conference, The Nueva School. Hillsborough, CA, November 2.
   Google Scholar
• Weber, F., H. Wulf, M. Gruber, and R. Biallas. 2004. S-ketamine and s-norketamine plasmaconcentrations after nasal and iv administration in anesthetized children. Paediatr†anaesth 14 (12):983–988.
   Google Scholar
• Wieber, J., R. Gugle, J. Hengstmann, and H. Dengler. 1975. Pharmacokinetics of ketamine in man. Anaesthesist 24 (6):260–63.
   PubMed Web of Science ®Google Scholar
• Williams, N. R., B. D. Heifets, C. Blasey, K. Sudheimer, J. Pannu, H. Pankow, J. Hawkins, J. Birnbaum, D. M. Lyons, C. I. Rodriguez, and A. F. Schatzberg. 2018. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. The American Journal of Psychiatry 175 (12):1205–1215. doi:10.1176/appi.ajp.2018.18020138.
   PubMed Web of Science ®Google Scholar
• Wolfson, P., and G. Hartelius, editors. 2016. The ketamine papers. Santa Cruz, CA: MAPS.
   Google Scholar
• Yensen, R. 2016. Psychedelic experiential psychology: Pioneering clinical explorations with salvador roquet. In The ketamine papers, ed. P. Wolfson and G. Hartellius, 69–93. Santa Cruz, CA: MAPS.
   Google Scholar
• Zarate, C., R. Duman, G. Liu, S. Sartori, J. Quiroz, and H. Murck. 2013. New paradigms for treatment-resistant depression. Annals of the New York Academy of Sciences 1292 (1):21–31. doi:10.1111/nyas.12223.
   PubMed Web of Science ®Google Scholar